Valery Javiana Fernández Rivas was six years old when she died, not from the aggressive leukemia she had been fighting since 2018, but from the extremely medicine meant to save her. For her mother, Yohana, the tragedy was not just the loss of a joyful child who once danced to rumba latina despite her illness, but the realization that her daughter’s death may have been preventable. Valery’s case has grow a harrowing symbol of the dangers of contaminated cancer medication in Colombia, exposing a systemic failure in global pharmaceutical oversight.
The crisis centered on methotrexate, a critical chemotherapy drug used globally to treat various cancers. In late January 2020, during a routine spinal injection at the Clínica Medical Duarte in Cúcuta, Valery suffered a violent reaction, screaming in pain and vomiting. Within four days, she fell into a coma; within two weeks, she was dead. Valery was one of four children who died after receiving the drug, and one of more than 100 patients who suffered severe reactions suspected to be linked to a contaminated batch.
Six years later, the pursuit of accountability remains stalled. The manufacturer, Naprod Life Sciences, an Indian pharmaceutical company specializing in oncology drugs, has faced virtually no sanctions in Colombia. While the company maintains that it follows internationally recognized Great Manufacturing Practices, evidence suggests a catastrophic breach in quality control that allowed a deadly pathogen to enter sealed vials.
A Pathogen in the Vial
An autopsy revealed that Valery’s blood contained Pseudomonas aeruginosa, a bacteria that is particularly lethal to patients with compromised immune systems, such as those undergoing chemotherapy. The contamination was not an isolated incident at the clinic; tests conducted by the Instituto Nacional de Vigilancia de Medicamentos y Alimentos (Invima), Colombia’s regulatory body, found the same bacteria inside sealed vials of Naprod’s methotrexate.
The origin of the contamination became a point of contention. Naprod conducted two internal investigations, both of which exonerated the company. The first claimed the bacteria originated within the hospitals. Still, an independent team of epidemiologists from the National Institute of Health of Colombia found no evidence of contamination within the medical centers, pointing instead to the manufacturing process.
Medical experts, including Paul Newton of the University of Oxford, have noted that when bacteria and fungi are found within sealed medication, it almost certainly indicates a failure in the production facility’s sterile environment. This pattern was later mirrored in India, where Naprod’s methotrexate triggered three separate alerts for contamination, eventually leading Indian regulators to cancel the company’s license to manufacture the drug.
Timeline of Regulatory Failure
| Period | Event | Outcome/Action |
|---|---|---|
| 2019 | Over 70 cases of severe reactions reported | Suspected link to Naprod methotrexate; mostly children affected. |
| Jan 2020 | Invima analysis of sealed sample | Bacteria detected; no immediate action taken. |
| Feb 8, 2020 | Official health alert issued | Invima ordered the recall of two specific lots. |
| Feb 2020 | Total recall ordered | All Naprod methotrexate ordered to be removed from market. |
The Cost of Cheap Medicine
The tragedy highlights a grim reality for pediatric oncology: approximately 90% of children with cancer live in low- and middle-income countries, where access to affordable, high-quality chemotherapy is a matter of survival. Methotrexate is often one of the only affordable options available. When the global supply chain fails, patients in these regions are the most vulnerable.
Claudia Martínez of the Access to Medicine Foundation describes this as a systemic problem, noting that more than two-thirds of countries worldwide cannot guarantee that the medicines reaching patients are safe and of high quality. In Colombia, the reliance on low-cost imports creates a precarious balance. Last year, Naprod shipped nearly eight million vials of various pharmaceuticals to Colombia, some priced at less than one dollar per vial—a price point that is often impossible for resource-strapped health systems to reject.
The regulatory gap is exacerbated by a lack of resources. Angela Caro-Rojas, a pharmacist and former president of the International Society of Pharmacovigilance, has pointed out that Invima has been hampered by personnel cuts and a tendency to rely on third-party reports rather than conducting its own rigorous inspections of foreign factories.
A Stalled Search for Justice
For the families of the deceased children, the legal process has been as agonizing as the medical tragedy. The Colombian Attorney General’s Office (Fiscalía General) has stated it is still gathering evidence, but the case remains in a state of inertia. Legal specialists note that proving direct causality in pharmaceutical negligence can be complex, but the six-year delay in providing answers to the families is widely viewed as unacceptable.
Yohana continues to advocate for those who cannot, arguing that the lack of transparency from Invima regarding why it did not act immediately after the January 2020 bacterial discovery is a secondary betrayal. “There has not been a single piece of news recognizing that Invima allowed contaminated medicines to pass controls,” she says, reflecting the frustration of families who experience the system is protecting the manufacturer over the patient.
While the Pan American Health Organization (PAHO) has stated it provides support to strengthen the capacity of authorities to detect substandard medicines, the continued export of Naprod products to other nations—including Algeria, Chile, and Peru—suggests that the global safety net remains porous.
Disclaimer: This article is for informational purposes only and does not constitute medical or legal advice.
The legal proceedings in Colombia continue to move through the Fiscalía General, with the next critical checkpoint being the formal conclusion of the evidence-gathering phase and the subsequent filing of charges against the responsible parties. Families continue to petition for a public accounting of the regulatory failures that preceded the 2020 deaths.
We invite readers to share their thoughts or similar experiences with pharmaceutical regulation in the comments below.
